Retinal vein occlusion treatment market

Roche’s Vabysmo secures a new FDA nod for retinal vein occlusion treatment, intensifying the competition with Regeneron and Bayer’s Eylea in the eye medication market. This approval for Vabysmo in RVO adds another shared medical indication for the competing eye medications. Vabysmo’s successful FDA approval for RVO...

Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landscape changed the market once dominated by Roche.Moving forward, RVO’s robust pipeline, along with several VEGF inhibitors, creates trouble for the big ones; Lucentis and Eylea. Retinal vein occlusion is the second most common s...

Retinal vein occlusion (RVO) is the second most common vision-threatening disorder that happens due to retinal vascular disease. If left untreated, RVO can result in vision impairment and a significant amount of other ocular complications. Any kind of blockage in the vein of the eye that carries blood from the reti...